KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $4.6 billion.

  • Alnylam Pharmaceuticals' Total Liabilities rose 1066.66% to $4.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year increase of 1066.66%. This contributed to the annual value of $4.2 billion for FY2024, which is 302.11% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Total Liabilities stood at $4.6 billion, which was up 1066.66% from $4.3 billion recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Total Liabilities' 5-year high stood at $4.6 billion during Q3 2025, with a 5-year trough of $2.3 billion in Q1 2021.
  • Its 5-year average for Total Liabilities is $3.6 billion, with a median of $3.8 billion in 2023.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Total Liabilities skyrocketed by 15046.69% in 2021, and later skyrocketed by 135.32% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Total Liabilities (Quarter) stood at $3.1 billion in 2021, then increased by 21.26% to $3.7 billion in 2022, then grew by 9.34% to $4.1 billion in 2023, then rose by 3.02% to $4.2 billion in 2024, then rose by 10.66% to $4.6 billion in 2025.
  • Its Total Liabilities stands at $4.6 billion for Q3 2025, versus $4.3 billion for Q2 2025 and $4.1 billion for Q1 2025.